Lutetium (177lu) lilotomab satetraxetan

N/A

Report date: 2025/09/11 11:16:04

Base Information

Drug NameLutetium (177lu) lilotomab satetraxetan
Drug Alias Name177Lu lilotomab satetraxetan,177Lu-Dota-tetulomab,177Lu-tetraxetan-tetulomab,177Lutetulomab,utetium 177Lu lilotomab satetraxetanBetalutin177Lu-DOTA-HH1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionIonising radiation emittersLeukocyte antigen CD37 antagonists
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNordic Nanovector
China Registration ClassN/A

Develop Information

Active CompaniesNordic Nanovector
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A